Ativan
lorazepam

ahead in anxiety
the response that you expect
and your patient needs
with minimal sedation
and rapid elimination

Ativan—the short
acting anxiolytic

Dosage
Mild anxiety: 2.5 mg daily in divided doses
Moderate severe anxiety: 5–10 mg daily in divided doses. In
all patients dosage should be increased until optimal control
of symptoms is achieved

Presentation
Ativan is presented as blue oblong tablets
containing 1 mg lorazepam and as yellow tablets
containing 2.5 mg lorazepam. (Also available in moxibical
forms)

Uses
Mild moderate and severe anxiety

Contraindications
Patients sensitive to

Adverse Reactions
Ataxia is an indication of excessive dosage. Daytime
drowsiness may be seen initially and is to be anticipated in
the effective treatment of anxiety. It will normally diminish
rapidly and may be minimised in the early days of treatment
by giving the larger proportion of the day’s dose before
retiring. Occasional confusion, hangover, headache on
waking, drowsiness or dizziness, blurred vision and nausea
have also been reported

Precautions
As with other drugs of this type, patients should be assured that their reactions may be modified by
handling machinery, driving etc. depending on the
individual patient’s circumstances. Tolerance to alcohol may be
increased and its consumption should be avoided. As the
action of centrally acting drugs, such as phenothiazines, may
be intensified, the co-prescription of these drugs should be
carefully monitored. Reduced dosage may be indicated
in elderly patients, or those suffering from cerebrovascular
changes or arteriosclerosis and likely to respond to
smaller doses. Prolonged or excessive use of benzodiazepines may occasionally result in the
development of some psychological dependence with
withdrawal symptoms on sudden discontinuation. Treatment
in these cases should be withdrawn gradually. Careful usage
seldom results in the development of dependence. Ativan,
tablets should not be administered during pregnancy. *

Legal category
POM

Product Licence Numbers
PL0011 0034 (1 mg)
PL0011 0036 (2.5 mg)

Basic N.H.S. costs
1 mg x 100 £1.05
2.5 mg x 100 £2.10

Hospital Price
As per local contract

Wytel Laboratories, John Wytel & Brother Ltd
Tappin, Maidenhead, Berks

* Trade Mark
Two years ago, Smith Kline and French Research Institute received the Queen's Award for Technological Achievement resulting from H₂ receptor antagonist research and the development of cimetidine.

Since it became generally available over three years ago, 'Tagamet', by its unique action in reducing gastric acid, has revolutionised the treatment of disorders such as duodenal ulcer, benign gastric ulcer and reflux oesophagitis, where acid plays a part.

For many patients it has brought a new standard of pain relief and healing. In the United Kingdom alone 'Tagamet' has been prescribed for an estimated one million patients.
Controls the inflammatory processes in more severe asthma
Restores the response to bronchodilators
Avoids the side effects associated with systemic steroids
Eliminates or greatly reduces the need for systemic steroids in steroid-dependent patients
Obviates physical disfigurement and stunting of growth in children
Available as metered-dose aerosol and Rotacaps with Rotahaler

"To support this claim of extraordinary activity (of Becotide), there are not only statistically valid comparisons but also numerous validated individual experiences. These include the impressive therapeutic results in patients with severe asthma not controllable with high daily doses of systemic steroids; the beneficial responses of those refractory to adrenergic agonists and unable to tolerate even suboptimal doses of theophylline; the suppression of asthma unresponsive to mediator-release inhibitors, such as cromolyn sodium; and, importantly, the high level of acceptance and compliance among people who do not comply with other standard therapeutic routines."

(Lancet, 1979, I, 932-933)